This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by AbbVie inc.
Reference
Bergman M, et al. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Advances in Therapy : 12 Oct 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01930-4
Rights and permissions
About this article
Cite this article
Upadacitinib for patients with RA: QOL improvements translate into economic benefits. PharmacoEcon Outcomes News 890, 32 (2021). https://doi.org/10.1007/s40274-021-08155-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08155-x